{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:15:53Z","timestamp":1791875753640,"version":"4.3.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are disease-modifying agents in type 2 diabetes mellitus (T2DM) and CKD, but studies on their use in cirrhosis are limited. We aimed to assess the effect of SGLT2i therapy on renal and hepatic function in patients with Child-Turcotte-Pugh (CTP) B cirrhosis and T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). Laboratory data were collected every 3 months. Liver stiffness (LS) was measured every 6 months via transient elastography (TE) and acoustic radiation force impulse with shear wave velocity (ARFI-SWV). The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. Secondary outcomes included LS changes measured via TE and ARFI. Additional end points included MELD-Na, MELD 3.0, CTP scores, hepatic decompensations, proteinuria, body mass index (BMI), hemoglobin A1c (Hb-A1c), blood glucose (BG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, the two groups were comparable in GFR (SGLT2i: 55.6 \u00b1 1.9 vs. insulin: 58.1 \u00b1 2.1 mL\/min\/1.73 m\u00b2, p = 0.37), CKD stage, ARFI-SWV (2.9 \u00b1 0.1 vs. 2.8 \u00b1 0.1 m\/s, p = 0.26), MELD-Na, and MELD 3.0. The SGLT2i group was older (p &amp;lt; 0.01) and had higher AST (p=0.01), ALT (p&amp;lt;0.01), and CTP scores (p=0.02), but lower LS by TE (p = 0.03). Over 48 months, GFR increased in the SGLT2i group (+13.5 \u00b1 1.3) and declined in the insulin group (\u22124.2 \u00b1 1.4; p &amp;lt; 0.01). A greater proportion of SGLT2i patients transitioned from CKD stage 3a to 2 (p = 0.04). Liver stiffness by TE decreased in the SGLT2i group (\u22124.0 \u00b1 1.1 kPa), while it increased in the insulin group (+3.0 \u00b1 2.5 kPa; p &amp;lt; 0.01). ARFI-SWV also declined in the SGLT2i group but increased in the insulin group (2.5 \u00b1 0.1 vs. 3.2 \u00b1 0.1 m\/s; p &amp;lt; 0.01). The SGLT2i group also demonstrated  significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p &amp;lt; 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1531295","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:11:37Z","timestamp":1747282297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes"],"prefix":"10.3389","volume":"16","author":[{"given":"Alessandro","family":"Colletta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Placentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Devuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Colletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25454","article-title":"Impact of chronic kidney disease on outcomes in cirrhosis","volume":"25","author":"Wong","year":"2019","journal-title":"Liver Transpl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3748\/wjg.v27.i11.990","article-title":"Chronic renal dysfunction in cirrhosis: A new frontier in hepatology","volume":"27","author":"Kumar","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032604","article-title":"Severity and remission of metabolic dysfunction-associated fatty\/steatotic liver disease with chronic kidney disease occurrence","volume":"13","author":"Gao","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.09.008","article-title":"Advanced fibrosis in metabolic dysfunction-associated steatotic liver disease is independently associated with reduced renal function","volume":"3","author":"Villarroel","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/155017","article-title":"The relationship between non-alcoholic fatty liver disease and incidence of chronic kidney disease for diabetic and non-diabetic subjects: A meta-analysis","volume":"32","author":"Chen","year":"2023","journal-title":"Adv Clin Exp Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.280","article-title":"Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management","volume":"15","author":"Garcia-Compean","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepato"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15851","article-title":"Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use","volume":"44","author":"Siafarikas","year":"2024","journal-title":"Liver Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00686-z","article-title":"The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit","volume":"10","author":"Patel","year":"2019","journal-title":"Diabetes Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2018.20.issue-8","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31270","article-title":"Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon","year":"2020","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27228","article-title":"Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C","volume":"60","author":"Elkrief","year":"2014","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.2016.36.issue-7","article-title":"Diabetes mellitus in patients with cirrhosis: clinical implications and management","volume":"36","author":"Elkrief","year":"2016","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000263","article-title":"Diabetes and cirrhosis: Current concepts on diagnosis and management","volume":"77","author":"Castera","year":"2023","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the american association for the study of liver diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new non-invasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2012.02820.x","article-title":"Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography","volume":"32","author":"de L\u00e9dinghen","year":"2012","journal-title":"Liver Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1366506","article-title":"Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index","volume":"35","author":"Salzl","year":"2014","journal-title":"Ultraschall Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v3.i8.205","article-title":"Value of acoustic radiation force impulse elastography for the assessment of ascites syndrome","volume":"3","author":"Bota","year":"2011","journal-title":"World J Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"12","author":"Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2049","article-title":"Comparison of Tofogliflozin and Glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-Label, Active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00086.2017","article-title":"Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes","volume":"313","author":"Tang","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i26.3243","article-title":"Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis, fibrosis, inflammation, and redox balance in non-alcoholic fatty liver disease","volume":"28","author":"Bellanti","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20420188211000243","DOI":"10.1177\/20420188211000243","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data","volume":"12","author":"Arai","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12876-023-03085-8","article-title":"Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis","volume":"23","author":"Huynh","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3390\/jcm12062253","article-title":"The effects of SGLT2 inhibitors on liver cirrhosis patients with refractory ascites: A literature review","author":"Miyamoto","year":"2023","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000499598","article-title":"Renal angiotensinogen and sodium-glucose cotransporter-2 inhibition: insights from experimental diabetic kidney disease","volume":"49","author":"Burns","year":"2019","journal-title":"Am J Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41598-023-28239-2","article-title":"The systemic and hepatic alternative renin\u2013angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation","volume":"13","author":"Hartl","year":"2023","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: A novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"101501","DOI":"10.1016\/j.aohep.2024.101501","article-title":"The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease","volume":"29","author":"Barrera","year":"2024","journal-title":"Ann Hepatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00190","article-title":"Prospect of sodium-glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1531295\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:11:42Z","timestamp":1747282302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1531295\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":47,"alternative-id":["10.3389\/fendo.2025.1531295"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1531295","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"1531295"}}